Health-care companies rose as traders rotated into high-risk areas such as biotechnology.
Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to stoke investor excitement. Merck, Moderna's partner on the melanoma product, also gained.
The iShares Biotechnology exchange-traded fund, a basket of major biotech companies, rose by more than 2%, closing at an all-time high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.